Journal
SCIENCE
Volume 352, Issue 6282, Pages 169-175Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.aaf2784
Keywords
-
Categories
Funding
- Cancer Research UK [C50947/A18176]
- National Institute for Health Research (NIHR) Biomedical Research Centre at the Royal Marsden Hospital
- Institute of Cancer Research [A109]
- Cancer Research UK (TRACERx project)
- Rosetrees Trust
- NovoNordisk Foundation [16584]
- European Union [259303]
- Prostate Cancer Foundation
- Breast Cancer Research Foundation
- European Research Council
- NIHR University College London Hospitals Biomedical Research Centre
- Cancer Research UK [18176] Funding Source: researchfish
Ask authors/readers for more resources
Therapeutic advances in oncology have not fully translated to the treatment of metastatic disease, which remains largely incurable. Metastatic subclones can emerge both early and late in the life of the primary tumor. A better understanding of the genetic evolution of metastatic disease has the potential to reveal differences in the therapeutic vulnerabilities of primary and metastatic tumors, shed light on the temporal patterns of and routes to metastatic colonization, and provide insight into the biology of the metastatic process. Here we review recent comparative studies of primary and metastatic tumors, including data suggesting that macroevolutionary shifts (the onset of chromosomal instability) contribute to the evolution of metastatic disease. We also discuss the practical challenges associated with these studies and how they might be overcome.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available